AG˹ٷ

STOCK TITAN

[8-K] KalVista Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Shell plc (SHEL) has issued a Form 6-K giving preliminary guidance for the second quarter (Q2) 2025 ahead of final results on 31 July 2025. The update indicates a mixed quarter, characterised by stronger downstream margins and disciplined cost control, set against lower upstream production and softer trading results.

Key operational trends

  • Integrated Gas: Production guided to 900-940 kboe/d (-2 % to -3 % QoQ) and LNG liquefaction to 6.4-6.8 MT. Trading & Optimisation profits are expected to be “significantly lower� than Q1.
  • Upstream: Production expected to fall to 1,660-1,760 kboe/d (-5 % to -11 %) due to scheduled maintenance and the divestiture of SPDC Nigeria. Exploration write-offs of ~US$0.2 bn are anticipated.
  • Marketing: Sales volumes fairly stable at 2,600-3,000 kb/d with adjusted earnings anticipated to exceed Q1.
  • Chemicals & Products: Indicative refining margin leaps to US$8.9/bbl from US$6.2/bbl, while chemicals margin rises to US$166/t from US$126/t. Nonetheless, segment adjusted earnings are expected below break-even and chemicals utilisation drops to 68-72 % due to unplanned Monaca downtime.
  • Renewables & Energy Solutions: Adjusted earnings range –US$0.4 bn to +US$0.2 bn, with trading & optimisation lower QoQ.

Cost & tax outlook

  • Underlying Opex: Group underlying operating expenses guided to US$8.5 bn for Q2, down from US$8.6 bn in Q1, reflecting lower spend in most segments.
  • Depreciation: Group pre-tax D&A expected at 5.1 bn (mid-point) versus 5.4 bn in Q1.
  • Tax: Adjusted tax charge seen falling to 3.8 bn from 4.1 bn, mainly in Integrated Gas and Upstream.

Cash flow indicators: Taxes paid expected at US$2.8-3.6 bn; working-capital movements could add up to +US$4 bn (vs –US$2.7 bn in Q1), potentially supporting operating cash flow.

Strategic takeaways: Higher downstream profitability and lower cost/tax burdens offer earnings support, yet declining hydrocarbon volumes, weaker trading and a chemicals loss temper the outlook. Investors will focus on the extent to which stronger margins offset volume headwinds when full Q2 results are released.

Shell plc (SHEL) ha pubblicato un modulo 6-K con le indicazioni preliminari per il secondo trimestre (Q2) 2025, in attesa dei risultati definitivi il 31 luglio 2025. L’aggiornamento segnala un trimestre misto, caratterizzato da margini downstream più solidi e un controllo rigoroso dei costi, bilanciati da una produzione upstream in calo e risultati di trading più deboli.

Tendenze operative principali

  • Integrated Gas: Produzione prevista tra 900-940 kboe/g (-2% a -3% QoQ) e liquefazione LNG tra 6,4-6,8 MT. I profitti da Trading & Ottimizzazione si prevede siano “significativamente inferiori� rispetto al Q1.
  • Upstream: Produzione stimata in calo a 1.660-1.760 kboe/g (-5% a -11%) a causa di manutenzioni programmate e della cessione di SPDC Nigeria. Si prevedono svalutazioni esplorative di circa 0,2 miliardi di dollari USA.
  • Marketing: Volumi di vendita stabili tra 2.600-3.000 kb/g con utile rettificato atteso in crescita rispetto al Q1.
  • Chemicals & Products: Margine di raffinazione indicativo in aumento a 8,9 USD/barile da 6,2 USD/barile, mentre il margine chimico sale a 166 USD/ton da 126 USD/ton. Tuttavia, l’utile rettificato del segmento è previsto al di sotto del pareggio e l’utilizzo degli impianti chimici scende al 68-72% a causa di un fermo non programmato a Monaca.
  • Renewables & Energy Solutions: Utile rettificato stimato tra -0,4 e +0,2 miliardi di dollari, con trading e ottimizzazione in calo QoQ.

Prospettive di costi e tasse

  • Opex sottostante: Spese operative sottostanti del gruppo previste a 8,5 miliardi di dollari per il Q2, in calo rispetto agli 8,6 miliardi del Q1, riflettendo una spesa minore nella maggior parte dei segmenti.
  • Deprezzamento: Ammortamenti e svalutazioni pre-tasse stimati a 5,1 miliardi (punto medio) rispetto ai 5,4 miliardi del Q1.
  • Tasse: L’onere fiscale rettificato dovrebbe scendere a 3,8 miliardi da 4,1 miliardi, principalmente in Integrated Gas e Upstream.

Indicatori di flusso di cassa: Tasse pagate previste tra 2,8 e 3,6 miliardi di dollari; le variazioni del capitale circolante potrebbero aggiungere fino a +4 miliardi (contro -2,7 miliardi nel Q1), sostenendo potenzialmente il flusso di cassa operativo.

Considerazioni strategiche: Maggiore redditività downstream e minori oneri di costi e tasse offrono supporto agli utili, ma il calo dei volumi di idrocarburi, il trading più debole e una perdita nel settore chimico moderano le prospettive. Gli investitori si concentreranno su quanto i margini più forti possano compensare le difficoltà legate ai volumi quando saranno pubblicati i risultati completi del Q2.

Shell plc (SHEL) ha emitido un Formulario 6-K con una guía preliminar para el segundo trimestre (Q2) de 2025, antes de los resultados finales el 31 de julio de 2025. La actualización indica un trimestre mixto, caracterizado por márgenes downstream más fuertes y un control disciplinado de costos, frente a una menor producción upstream y resultados de trading más débiles.

Tendencias operativas clave

  • Integrated Gas: Producción estimada entre 900-940 kboe/d (-2 % a -3 % QoQ) y licuefacción de GNL de 6,4-6,8 MT. Se espera que las ganancias de Trading & Optimización sean “significativamente menores� que en el Q1.
  • Upstream: Producción prevista en descenso a 1.660-1.760 kboe/d (-5 % a -11 %) debido a mantenimiento programado y la desinversión de SPDC Nigeria. Se anticipan pérdidas por exploración de aproximadamente 0,2 mil millones de dólares.
  • Marketing: Volúmenes de ventas relativamente estables entre 2.600-3.000 kb/d con ganancias ajustadas esperadas que superan las del Q1.
  • Chemicals & Products: El margen indicativo de refinación salta a 8,9 USD/barril desde 6,2 USD/barril, mientras que el margen químico sube a 166 USD/ton desde 126 USD/ton. Sin embargo, se espera que las ganancias ajustadas del segmento estén por debajo del punto de equilibrio y la utilización química disminuye al 68-72 % debido a un tiempo de inactividad no planificado en Monaca.
  • Renewables & Energy Solutions: Ganancias ajustadas entre -0,4 y +0,2 mil millones de dólares, con trading y optimización a la baja QoQ.

Perspectivas de costos e impuestos

  • Opex subyacente: Se guían gastos operativos subyacentes del grupo a 8,5 mil millones de dólares para el Q2, por debajo de los 8,6 mil millones del Q1, reflejando un gasto menor en la mayoría de los segmentos.
  • ٱ𳦾ó: Se espera una depreciación y amortización preimpuestos del grupo de 5,1 mil millones (punto medio) frente a 5,4 mil millones en el Q1.
  • Impuestos: Se prevé que el cargo fiscal ajustado caiga a 3,8 mil millones desde 4,1 mil millones, principalmente en Integrated Gas y Upstream.

Indicadores de flujo de caja: Se esperan impuestos pagados entre 2,8 y 3,6 mil millones de dólares; los movimientos de capital de trabajo podrían sumar hasta +4 mil millones (frente a -2,7 mil millones en el Q1), apoyando potencialmente el flujo de caja operativo.

Conclusiones estratégicas: Una mayor rentabilidad downstream y menores cargas de costos/impuestos brindan soporte a las ganancias, aunque el descenso en volúmenes de hidrocarburos, el trading más débil y una pérdida en químicos moderan las perspectivas. Los inversores se centrarán en qué medida los márgenes más fuertes compensan los vientos en contra de volumen cuando se publiquen los resultados completos del Q2.

Shell plc (SHEL)� 2025� 2분기(Q2) 예비 가이던스를 포함� Form 6-K� 발행했으�, 최종 결과� 2025� 7� 31일에 발표� 예정입니�. 이번 업데이트� 하류 부문의 마진 강세와 엄격� 비용 관리가 두드러진 반면, 상류 생산� 감소와 약화� 트레이딩 실적� 혼재� 분기� 예고합니�.

주요 운영 동향

  • 통합 가�(Integrated Gas): 생산량은 900-940 kboe/d(-2%~ -3% QoQ)� 예상되며, LNG 액화량은 6.4-6.8 MT입니�. 트레이딩 � 최적� 이익은 1분기 대� “상당히 낮을 것”으� 예상됩니�.
  • 상류(ٰ𲹳): 예정� 유지보수와 SPDC 나이지리아 매각으로 인해 생산량이 1,660-1,760 kboe/d(-5%~ -11%)� 감소� 것으� 보입니다. � 2� 달러 규모� 탐사 손실� 예상됩니�.
  • 마케�(ѲپԲ): 판매량은 2,600-3,000 kb/d� 비교� 안정적이�, 조정 이익은 1분기보다 증가� 것으� 기대됩니�.
  • 화학 � 제품(Chemicals & Products): 정제 마진은 배럴� 6.2달러에서 8.9달러� 급등했으�, 화학 마진은 톤당 126달러에서 166달러� 상승했습니다. 그럼에도 불구하고, � 부문의 조정 이익은 손익분기� 이하� 것으� 예상되며, Monaca 공장� 예기� 않은 가� 중단으로 화학 설비 가동률� 68-72%� 떨어졌습니다.
  • 재생 에너지 � 에너지 솔루�(Renewables & Energy Solutions): 조정 이익은 -4� 달러에서 +2� 달러 사이이며, 트레이딩 � 최적� 실적은 1분기 대� 감소했습니다.

비용 � 세금 전망

  • 기본 운영비용(Underlying Opex): 그룹� 기본 운영비용은 2분기� 85� 달러� 예상되며, 이는 1분기� 86� 달러에서 감소� 수치� 대부분의 부문에� 지출이 줄어� 결과입니�.
  • 감가상각(ٱ𳦾پDz): 세전 감가상각비는 51� 달러(중간�)� 1분기� 54� 달러보다 낮을 것으� 예상됩니�.
  • 세금(ղ): 조정 세금 비용은 주로 통합 가스와 상류 부문에� 38� 달러� 41� 달러에서 감소� 전망입니�.

현금 흐름 지�: 납부 세금은 28억~36� 달러� 예상되며, 운전자본 변동으� 최대 +40� 달러가 추가� � 있어(1분기� -27� 달러 대�) 영업 현금 흐름� 긍정� 영향� � � 있습니다.

전략� 시사�: 하류 부� 수익� 개선� 비용 � 세금 부� 감소가 이익� 지지하지�, 탄화수소 생산� 감소, 약화� 트레이딩 실적, 화학 부� 손실� 전망� 제한합니�. 투자자들은 2분기 전체 실적 발표 � 강화� 마진� 물량 감소� 영향� 얼마� 상쇄하는지� 주목� 것입니다.

Shell plc (SHEL) a publié un formulaire 6-K donnant des indications préliminaires pour le deuxième trimestre (T2) 2025, avant les résultats définitifs du 31 juillet 2025. Cette mise à jour indique un trimestre mitigé, caractérisé par des marges en aval plus fortes et un contrôle rigoureux des coûts, compensés par une production en amont plus faible et des résultats de trading en baisse.

Tendances opérationnelles clés

  • Integrated Gas : La production est guidée entre 900-940 kboe/j (-2 % à -3 % QoQ) et la liquéfaction de GNL entre 6,4-6,8 MT. Les profits de Trading & Optimisation devraient être « significativement inférieurs » à ceux du T1.
  • Upstream : La production devrait chuter à 1 660-1 760 kboe/j (-5 % à -11 %) en raison de maintenances programmées et de la cession de SPDC Nigeria. Des dépréciations d’exploration d’environ 0,2 milliard de dollars US sont anticipées.
  • Marketing : Les volumes de vente restent assez stables entre 2 600-3 000 kb/j avec des résultats ajustés attendus supérieurs à ceux du T1.
  • Chemicals & Products : La marge indicative de raffinage bondit à 8,9 $/baril contre 6,2 $/baril, tandis que la marge chimique passe de 126 $/t à 166 $/t. Néanmoins, les résultats ajustés du segment devraient être inférieurs au seuil de rentabilité et l’utilisation des unités chimiques baisse à 68-72 % en raison d’un arrêt imprévu à Monaca.
  • Renewables & Energy Solutions : Les résultats ajustés varient entre -0,4 et +0,2 milliard de dollars, avec un trading et une optimisation en baisse QoQ.

Perspectives coûts et fiscalité

  • Opex sous-jacents : Les dépenses opérationnelles sous-jacentes du groupe sont guidées à 8,5 milliards de dollars pour le T2, en baisse par rapport à 8,6 milliards au T1, reflétant une moindre dépense dans la plupart des segments.
  • Amortissements : Les D&A avant impôts du groupe sont attendus à 5,1 milliards (point médian) contre 5,4 milliards au T1.
  • Impôts : La charge fiscale ajustée devrait diminuer à 3,8 milliards contre 4,1 milliards, principalement dans Integrated Gas et Upstream.

Indicateurs de flux de trésorerie : Les taxes payées sont attendues entre 2,8 et 3,6 milliards de dollars ; les mouvements de fonds de roulement pourraient ajouter jusqu’� +4 milliards de dollars (contre -2,7 milliards au T1), soutenant potentiellement le flux de trésorerie opérationnel.

Enseignements stratégiques : Une rentabilité en aval plus élevée et des charges de coûts/fiscalité plus faibles soutiennent les résultats, mais la baisse des volumes d’hydrocarbures, un trading plus faible et une perte dans le secteur chimique tempèrent les perspectives. Les investisseurs se concentreront sur la mesure dans laquelle des marges plus fortes compensent les vents contraires liés aux volumes lors de la publication des résultats complets du T2.

Shell plc (SHEL) hat ein Formular 6-K mit vorläufigen Prognosen für das zweite Quartal (Q2) 2025 veröffentlicht, bevor die endgültigen Ergebnisse am 31. Juli 2025 bekanntgegeben werden. Das Update weist auf ein gemischtes Quartal hin, geprägt von stärkeren Downstream-Margen und diszipliniertem Kostenmanagement, bei gleichzeitig geringerer Upstream-Produktion und schwächeren Trading-Ergebnissen.

Wesentliche operative Trends

  • Integrated Gas: Produktion wird auf 900-940 kboe/d (-2 % bis -3 % QoQ) prognostiziert, LNG-Verflüssigung bei 6,4-6,8 MT. Die Gewinne aus Trading & Optimierung werden voraussichtlich „signifikant niedriger� als im Q1 ausfallen.
  • Upstream: Produktion wird aufgrund geplanter Wartungen und des Verkaufs von SPDC Nigeria auf 1.660-1.760 kboe/d (-5 % bis -11 %) sinken. Explorationsabschreibungen von etwa 0,2 Mrd. USD werden erwartet.
  • Marketing: Verkaufsvolumen bleiben mit 2.600-3.000 kb/d relativ stabil, mit erwarteten bereinigten Gewinnen, die das Q1 übertreffen.
  • Chemicals & Products: Der indikative Raffineriemargen springt von 6,2 USD/Barrel auf 8,9 USD/Barrel, während die Chemie-Marge von 126 USD/t auf 166 USD/t steigt. Dennoch werden die bereinigten Gewinne des Segments unter der Gewinnschwelle erwartet, und die Auslastung der Chemieanlagen sinkt aufgrund ungeplanter Ausfallzeiten in Monaca auf 68-72 %.
  • Renewables & Energy Solutions: Bereinigte Gewinne liegen zwischen -0,4 Mrd. USD und +0,2 Mrd. USD, mit rückläufigen Trading- und Optimierungsergebnissen im Vergleich zum Vorquartal.

Kosten- und Steuerprognose

  • Underlying Opex: Die unterliegenden Betriebskosten des Konzerns werden für das Q2 auf 8,5 Mrd. USD prognostiziert, gegenüber 8,6 Mrd. USD im Q1, was geringere Ausgaben in den meisten Segmenten widerspiegelt.
  • Abschreibungen: Die vorsteuerlichen Abschreibungen und Amortisationen werden auf 5,1 Mrd. USD (Mittelwert) gegenüber 5,4 Mrd. USD im Q1 geschätzt.
  • Steuern: Die bereinigte Steuerlast wird voraussichtlich von 4,1 Mrd. USD auf 3,8 Mrd. USD sinken, hauptsächlich in Integrated Gas und Upstream.

Cashflow-Indikatoren: Erwartete Steuerzahlungen liegen zwischen 2,8 und 3,6 Mrd. USD; Veränderungen im Working Capital könnten bis zu +4 Mrd. USD betragen (gegenüber -2,7 Mrd. USD im Q1) und damit den operativen Cashflow unterstützen.

Strategische Erkenntnisse: Höhere Downstream-Profitabilität und geringere Kosten- und Steuerbelastungen stützen die Ergebnisse, doch sinkende Kohlenwasserstoffvolumina, schwächere Trading-Ergebnisse und Verluste im Chemiebereich dämpfen die Aussichten. Investoren werden darauf achten, inwieweit stärkere Margen die Volumenrückgänge bei der Veröffentlichung der vollständigen Q2-Ergebnisse ausgleichen.

Positive
  • Refining margin surge: Indicative refining margin rises to US$8.9/bbl, a 44 % QoQ jump, likely boosting downstream earnings and cash flow.
  • Cost discipline: Group underlying opex guided lower to US$8.5 bn and depreciation mid-point trimmed, supporting profitability.
  • Tax relief: Adjusted tax charge expected to fall by ~US$0.3 bn, particularly in Integrated Gas and Upstream.
  • Marketing strength: Segment adjusted earnings projected above Q1, indicating resilient demand and pricing.
Negative
  • Production decline: Upstream volumes guided 5-11 % lower due to maintenance and the Nigeria SPDC divestment.
  • Trading & Optimisation weakness: Materially lower contributions expected in Integrated Gas, Chemicals & Products, and Renewables segments.
  • Chemicals loss: Despite higher margins, chemicals sub-segment still expected to post an adjusted loss with utilisation dropping to 68-72 %.
  • LNG output softness: Integrated Gas liquefaction volumes slightly lower and trading profits down, pressuring segment earnings.

Insights

TL;DR: Refining strength offsets production dip; overall Q2 guide points to flat to slightly higher earnings.

Shell’s update reveals an improved downstream environment with the indicative refining margin jumping 44 % QoQ to US$8.9/bbl and utilisation up to 92-96 %. This should materially lift Chemicals & Products EBITDA even though trading income is flagged lower. Marketing also looks stronger, leveraging resilient retail demand.

Conversely, both Integrated Gas and Upstream volumes contract—partly structural (SPDC sale) and partly maintenance. Combined with markedly lower trading gains, these segments will drag on group earnings. Encouragingly, the tax charge and opex guidance move down, cushioning the EBITDA shortfall. Net, I expect Q2 adjusted EPS to land near Q1’s US$5.6 bn, implying a neutral to mildly positive read-through for valuation.

TL;DR: Guidance signals quality cash generation; watch chemicals loss and LNG trading slump.

From a capital-allocation lens, the message is twofold: 1) downstream cash flow looks poised for a strong rebound given margin and utilisation uplift; 2) upstream cash flow is pressured by lower volumes but benefits from reduced tax outflows. The working-capital swing of up to +US$4 bn could meaningfully enhance CFFO, supporting ongoing buybacks and dividends.

Risks remain: LNG trading volatility is elevated, and chemicals remains structurally weak despite better headline margins. Still, lower opex and depreciation underscore management’s cost discipline. I view the update as broadly balanced but with a slight positive bias for near-term free cash flow.

Shell plc (SHEL) ha pubblicato un modulo 6-K con le indicazioni preliminari per il secondo trimestre (Q2) 2025, in attesa dei risultati definitivi il 31 luglio 2025. L’aggiornamento segnala un trimestre misto, caratterizzato da margini downstream più solidi e un controllo rigoroso dei costi, bilanciati da una produzione upstream in calo e risultati di trading più deboli.

Tendenze operative principali

  • Integrated Gas: Produzione prevista tra 900-940 kboe/g (-2% a -3% QoQ) e liquefazione LNG tra 6,4-6,8 MT. I profitti da Trading & Ottimizzazione si prevede siano “significativamente inferiori� rispetto al Q1.
  • Upstream: Produzione stimata in calo a 1.660-1.760 kboe/g (-5% a -11%) a causa di manutenzioni programmate e della cessione di SPDC Nigeria. Si prevedono svalutazioni esplorative di circa 0,2 miliardi di dollari USA.
  • Marketing: Volumi di vendita stabili tra 2.600-3.000 kb/g con utile rettificato atteso in crescita rispetto al Q1.
  • Chemicals & Products: Margine di raffinazione indicativo in aumento a 8,9 USD/barile da 6,2 USD/barile, mentre il margine chimico sale a 166 USD/ton da 126 USD/ton. Tuttavia, l’utile rettificato del segmento è previsto al di sotto del pareggio e l’utilizzo degli impianti chimici scende al 68-72% a causa di un fermo non programmato a Monaca.
  • Renewables & Energy Solutions: Utile rettificato stimato tra -0,4 e +0,2 miliardi di dollari, con trading e ottimizzazione in calo QoQ.

Prospettive di costi e tasse

  • Opex sottostante: Spese operative sottostanti del gruppo previste a 8,5 miliardi di dollari per il Q2, in calo rispetto agli 8,6 miliardi del Q1, riflettendo una spesa minore nella maggior parte dei segmenti.
  • Deprezzamento: Ammortamenti e svalutazioni pre-tasse stimati a 5,1 miliardi (punto medio) rispetto ai 5,4 miliardi del Q1.
  • Tasse: L’onere fiscale rettificato dovrebbe scendere a 3,8 miliardi da 4,1 miliardi, principalmente in Integrated Gas e Upstream.

Indicatori di flusso di cassa: Tasse pagate previste tra 2,8 e 3,6 miliardi di dollari; le variazioni del capitale circolante potrebbero aggiungere fino a +4 miliardi (contro -2,7 miliardi nel Q1), sostenendo potenzialmente il flusso di cassa operativo.

Considerazioni strategiche: Maggiore redditività downstream e minori oneri di costi e tasse offrono supporto agli utili, ma il calo dei volumi di idrocarburi, il trading più debole e una perdita nel settore chimico moderano le prospettive. Gli investitori si concentreranno su quanto i margini più forti possano compensare le difficoltà legate ai volumi quando saranno pubblicati i risultati completi del Q2.

Shell plc (SHEL) ha emitido un Formulario 6-K con una guía preliminar para el segundo trimestre (Q2) de 2025, antes de los resultados finales el 31 de julio de 2025. La actualización indica un trimestre mixto, caracterizado por márgenes downstream más fuertes y un control disciplinado de costos, frente a una menor producción upstream y resultados de trading más débiles.

Tendencias operativas clave

  • Integrated Gas: Producción estimada entre 900-940 kboe/d (-2 % a -3 % QoQ) y licuefacción de GNL de 6,4-6,8 MT. Se espera que las ganancias de Trading & Optimización sean “significativamente menores� que en el Q1.
  • Upstream: Producción prevista en descenso a 1.660-1.760 kboe/d (-5 % a -11 %) debido a mantenimiento programado y la desinversión de SPDC Nigeria. Se anticipan pérdidas por exploración de aproximadamente 0,2 mil millones de dólares.
  • Marketing: Volúmenes de ventas relativamente estables entre 2.600-3.000 kb/d con ganancias ajustadas esperadas que superan las del Q1.
  • Chemicals & Products: El margen indicativo de refinación salta a 8,9 USD/barril desde 6,2 USD/barril, mientras que el margen químico sube a 166 USD/ton desde 126 USD/ton. Sin embargo, se espera que las ganancias ajustadas del segmento estén por debajo del punto de equilibrio y la utilización química disminuye al 68-72 % debido a un tiempo de inactividad no planificado en Monaca.
  • Renewables & Energy Solutions: Ganancias ajustadas entre -0,4 y +0,2 mil millones de dólares, con trading y optimización a la baja QoQ.

Perspectivas de costos e impuestos

  • Opex subyacente: Se guían gastos operativos subyacentes del grupo a 8,5 mil millones de dólares para el Q2, por debajo de los 8,6 mil millones del Q1, reflejando un gasto menor en la mayoría de los segmentos.
  • ٱ𳦾ó: Se espera una depreciación y amortización preimpuestos del grupo de 5,1 mil millones (punto medio) frente a 5,4 mil millones en el Q1.
  • Impuestos: Se prevé que el cargo fiscal ajustado caiga a 3,8 mil millones desde 4,1 mil millones, principalmente en Integrated Gas y Upstream.

Indicadores de flujo de caja: Se esperan impuestos pagados entre 2,8 y 3,6 mil millones de dólares; los movimientos de capital de trabajo podrían sumar hasta +4 mil millones (frente a -2,7 mil millones en el Q1), apoyando potencialmente el flujo de caja operativo.

Conclusiones estratégicas: Una mayor rentabilidad downstream y menores cargas de costos/impuestos brindan soporte a las ganancias, aunque el descenso en volúmenes de hidrocarburos, el trading más débil y una pérdida en químicos moderan las perspectivas. Los inversores se centrarán en qué medida los márgenes más fuertes compensan los vientos en contra de volumen cuando se publiquen los resultados completos del Q2.

Shell plc (SHEL)� 2025� 2분기(Q2) 예비 가이던스를 포함� Form 6-K� 발행했으�, 최종 결과� 2025� 7� 31일에 발표� 예정입니�. 이번 업데이트� 하류 부문의 마진 강세와 엄격� 비용 관리가 두드러진 반면, 상류 생산� 감소와 약화� 트레이딩 실적� 혼재� 분기� 예고합니�.

주요 운영 동향

  • 통합 가�(Integrated Gas): 생산량은 900-940 kboe/d(-2%~ -3% QoQ)� 예상되며, LNG 액화량은 6.4-6.8 MT입니�. 트레이딩 � 최적� 이익은 1분기 대� “상당히 낮을 것”으� 예상됩니�.
  • 상류(ٰ𲹳): 예정� 유지보수와 SPDC 나이지리아 매각으로 인해 생산량이 1,660-1,760 kboe/d(-5%~ -11%)� 감소� 것으� 보입니다. � 2� 달러 규모� 탐사 손실� 예상됩니�.
  • 마케�(ѲپԲ): 판매량은 2,600-3,000 kb/d� 비교� 안정적이�, 조정 이익은 1분기보다 증가� 것으� 기대됩니�.
  • 화학 � 제품(Chemicals & Products): 정제 마진은 배럴� 6.2달러에서 8.9달러� 급등했으�, 화학 마진은 톤당 126달러에서 166달러� 상승했습니다. 그럼에도 불구하고, � 부문의 조정 이익은 손익분기� 이하� 것으� 예상되며, Monaca 공장� 예기� 않은 가� 중단으로 화학 설비 가동률� 68-72%� 떨어졌습니다.
  • 재생 에너지 � 에너지 솔루�(Renewables & Energy Solutions): 조정 이익은 -4� 달러에서 +2� 달러 사이이며, 트레이딩 � 최적� 실적은 1분기 대� 감소했습니다.

비용 � 세금 전망

  • 기본 운영비용(Underlying Opex): 그룹� 기본 운영비용은 2분기� 85� 달러� 예상되며, 이는 1분기� 86� 달러에서 감소� 수치� 대부분의 부문에� 지출이 줄어� 결과입니�.
  • 감가상각(ٱ𳦾پDz): 세전 감가상각비는 51� 달러(중간�)� 1분기� 54� 달러보다 낮을 것으� 예상됩니�.
  • 세금(ղ): 조정 세금 비용은 주로 통합 가스와 상류 부문에� 38� 달러� 41� 달러에서 감소� 전망입니�.

현금 흐름 지�: 납부 세금은 28억~36� 달러� 예상되며, 운전자본 변동으� 최대 +40� 달러가 추가� � 있어(1분기� -27� 달러 대�) 영업 현금 흐름� 긍정� 영향� � � 있습니다.

전략� 시사�: 하류 부� 수익� 개선� 비용 � 세금 부� 감소가 이익� 지지하지�, 탄화수소 생산� 감소, 약화� 트레이딩 실적, 화학 부� 손실� 전망� 제한합니�. 투자자들은 2분기 전체 실적 발표 � 강화� 마진� 물량 감소� 영향� 얼마� 상쇄하는지� 주목� 것입니다.

Shell plc (SHEL) a publié un formulaire 6-K donnant des indications préliminaires pour le deuxième trimestre (T2) 2025, avant les résultats définitifs du 31 juillet 2025. Cette mise à jour indique un trimestre mitigé, caractérisé par des marges en aval plus fortes et un contrôle rigoureux des coûts, compensés par une production en amont plus faible et des résultats de trading en baisse.

Tendances opérationnelles clés

  • Integrated Gas : La production est guidée entre 900-940 kboe/j (-2 % à -3 % QoQ) et la liquéfaction de GNL entre 6,4-6,8 MT. Les profits de Trading & Optimisation devraient être « significativement inférieurs » à ceux du T1.
  • Upstream : La production devrait chuter à 1 660-1 760 kboe/j (-5 % à -11 %) en raison de maintenances programmées et de la cession de SPDC Nigeria. Des dépréciations d’exploration d’environ 0,2 milliard de dollars US sont anticipées.
  • Marketing : Les volumes de vente restent assez stables entre 2 600-3 000 kb/j avec des résultats ajustés attendus supérieurs à ceux du T1.
  • Chemicals & Products : La marge indicative de raffinage bondit à 8,9 $/baril contre 6,2 $/baril, tandis que la marge chimique passe de 126 $/t à 166 $/t. Néanmoins, les résultats ajustés du segment devraient être inférieurs au seuil de rentabilité et l’utilisation des unités chimiques baisse à 68-72 % en raison d’un arrêt imprévu à Monaca.
  • Renewables & Energy Solutions : Les résultats ajustés varient entre -0,4 et +0,2 milliard de dollars, avec un trading et une optimisation en baisse QoQ.

Perspectives coûts et fiscalité

  • Opex sous-jacents : Les dépenses opérationnelles sous-jacentes du groupe sont guidées à 8,5 milliards de dollars pour le T2, en baisse par rapport à 8,6 milliards au T1, reflétant une moindre dépense dans la plupart des segments.
  • Amortissements : Les D&A avant impôts du groupe sont attendus à 5,1 milliards (point médian) contre 5,4 milliards au T1.
  • Impôts : La charge fiscale ajustée devrait diminuer à 3,8 milliards contre 4,1 milliards, principalement dans Integrated Gas et Upstream.

Indicateurs de flux de trésorerie : Les taxes payées sont attendues entre 2,8 et 3,6 milliards de dollars ; les mouvements de fonds de roulement pourraient ajouter jusqu’� +4 milliards de dollars (contre -2,7 milliards au T1), soutenant potentiellement le flux de trésorerie opérationnel.

Enseignements stratégiques : Une rentabilité en aval plus élevée et des charges de coûts/fiscalité plus faibles soutiennent les résultats, mais la baisse des volumes d’hydrocarbures, un trading plus faible et une perte dans le secteur chimique tempèrent les perspectives. Les investisseurs se concentreront sur la mesure dans laquelle des marges plus fortes compensent les vents contraires liés aux volumes lors de la publication des résultats complets du T2.

Shell plc (SHEL) hat ein Formular 6-K mit vorläufigen Prognosen für das zweite Quartal (Q2) 2025 veröffentlicht, bevor die endgültigen Ergebnisse am 31. Juli 2025 bekanntgegeben werden. Das Update weist auf ein gemischtes Quartal hin, geprägt von stärkeren Downstream-Margen und diszipliniertem Kostenmanagement, bei gleichzeitig geringerer Upstream-Produktion und schwächeren Trading-Ergebnissen.

Wesentliche operative Trends

  • Integrated Gas: Produktion wird auf 900-940 kboe/d (-2 % bis -3 % QoQ) prognostiziert, LNG-Verflüssigung bei 6,4-6,8 MT. Die Gewinne aus Trading & Optimierung werden voraussichtlich „signifikant niedriger� als im Q1 ausfallen.
  • Upstream: Produktion wird aufgrund geplanter Wartungen und des Verkaufs von SPDC Nigeria auf 1.660-1.760 kboe/d (-5 % bis -11 %) sinken. Explorationsabschreibungen von etwa 0,2 Mrd. USD werden erwartet.
  • Marketing: Verkaufsvolumen bleiben mit 2.600-3.000 kb/d relativ stabil, mit erwarteten bereinigten Gewinnen, die das Q1 übertreffen.
  • Chemicals & Products: Der indikative Raffineriemargen springt von 6,2 USD/Barrel auf 8,9 USD/Barrel, während die Chemie-Marge von 126 USD/t auf 166 USD/t steigt. Dennoch werden die bereinigten Gewinne des Segments unter der Gewinnschwelle erwartet, und die Auslastung der Chemieanlagen sinkt aufgrund ungeplanter Ausfallzeiten in Monaca auf 68-72 %.
  • Renewables & Energy Solutions: Bereinigte Gewinne liegen zwischen -0,4 Mrd. USD und +0,2 Mrd. USD, mit rückläufigen Trading- und Optimierungsergebnissen im Vergleich zum Vorquartal.

Kosten- und Steuerprognose

  • Underlying Opex: Die unterliegenden Betriebskosten des Konzerns werden für das Q2 auf 8,5 Mrd. USD prognostiziert, gegenüber 8,6 Mrd. USD im Q1, was geringere Ausgaben in den meisten Segmenten widerspiegelt.
  • Abschreibungen: Die vorsteuerlichen Abschreibungen und Amortisationen werden auf 5,1 Mrd. USD (Mittelwert) gegenüber 5,4 Mrd. USD im Q1 geschätzt.
  • Steuern: Die bereinigte Steuerlast wird voraussichtlich von 4,1 Mrd. USD auf 3,8 Mrd. USD sinken, hauptsächlich in Integrated Gas und Upstream.

Cashflow-Indikatoren: Erwartete Steuerzahlungen liegen zwischen 2,8 und 3,6 Mrd. USD; Veränderungen im Working Capital könnten bis zu +4 Mrd. USD betragen (gegenüber -2,7 Mrd. USD im Q1) und damit den operativen Cashflow unterstützen.

Strategische Erkenntnisse: Höhere Downstream-Profitabilität und geringere Kosten- und Steuerbelastungen stützen die Ergebnisse, doch sinkende Kohlenwasserstoffvolumina, schwächere Trading-Ergebnisse und Verluste im Chemiebereich dämpfen die Aussichten. Investoren werden darauf achten, inwieweit stärkere Margen die Volumenrückgänge bei der Veröffentlichung der vollständigen Q2-Ergebnisse ausgleichen.

false 0001348911 0001348911 2025-07-07 2025-07-07
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2025

 

 

KALVISTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36830   20-0915291

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

55 Cambridge Parkway

Suite 901E

Cambridge, Massachusetts

  02142
(Address of principal executive offices)   (Zip Code)

(857) 999-0075

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 par value per share   KALV   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 7.01

Regulation FD Disclosure.

On July 7, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) issued a press release titled “KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema.” A copy of the press release is attached hereto as Exhibit 99.1.

On July 7, 2025, the Company also updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.2 to this report.

The information in this Item 7.01, including Exhibits 99.1 and 99.2 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01

Other Events.

On July 7, 2025, the Company announced that the U.S. Food and Drug Administration (the “FDA”) approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (“HAE”) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE.

The FDA approval was based on data from the phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine. EKTERLY achieved significantly faster symptom relief, reduction in attack severity and attack resolution than placebo, and was well-tolerated with a safety profile similar to placebo. The trial randomized 136 HAE patients from 66 clinical sites across 20 countries, making it the largest clinical trial ever conducted in HAE. These results were further supported by the KONFIDENT-S open-label extension trial, which as of September 2024, showed that 600 mg of sebetralstat enabled patients to treat attacks in a median of 10 minutes following onset. The most recent data from KONFIDENT-S shows that beginning of symptom relief occurred in a median of 1.3 hours among attacks involving the larynx, the abdomen, and for breakthrough attacks among patients receiving long-term prophylaxis, and demonstrated a favorable safety profile consistent with KONFIDENT.


Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: plans regarding commercialization of EKTERLY, expectations from current clinical trials, the execution of the Phase 3 clinical trial for sebetralstat as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials, release data results and to obtain additional regulatory approvals for sebetralstat and other candidates in development, and the ability of sebetralstat to treat HAE.

Statements including words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in the “Risk Factors” section of the Company’s Form 10-K for the year ended April 30, 2024 and the Company’s other filings with the Securities and Exchange Commission, including the Company’s ability to develop, obtain additional regulatory approval for or commercialize any product candidate, the Company’s ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of inflation, rising interest rates, actual or perceived instability in the global banking system, geopolitical conflicts and the sufficiency of the Company’s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and the Company specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   Description
99.1    Press Release, dated July 7, 2025
99.2    Presentation.
104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    KALVISTA PHARMACEUTICALS, INC.
Date: July 7, 2025     By:  

/s/ Brian Piekos

      Brian Piekos
      Chief Financial Officer

FAQ

When will Shell (SHEL) report final Q2 2025 results?

Shell plans to publish its Q2 2025 results on 31 July 2025.

How much are Shell’s indicative refining margins for Q2 2025?

The update guides an indicative refining margin of US$8.9 per barrel, up from US$6.2/bbl in Q1 2025.

What is Shell’s expected Upstream production for Q2 2025?

Upstream production is forecast between 1,660 and 1,760 kboe/d, down from 1,855 kboe/d in Q1.

Will Shell’s Marketing segment improve in Q2 2025?

Yes. Management expects Marketing adjusted earnings to exceed Q1 2025 despite similar sales volumes.

Why is the Chemicals segment still loss-making despite higher margins?

Unplanned maintenance at Monaca lowers utilisation to 68-72 %, offsetting the benefit of the higher US$166/t chemicals margin.

How will taxes and opex affect Shell’s Q2 2025 cash flow?

Underlying opex is guided slightly lower at US$8.5 bn and the adjusted tax charge at US$3.8 bn, both supportive of cash generation.
Kalvista Pharm

NASDAQ:KALV

KALV Rankings

KALV Latest News

KALV Stock Data

562.04M
44.02M
1.36%
113.48%
11.21%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE